Histopathological Findings of Appendix Specimens in Quiescent Ulcerative Colitis: Correlations With Clinical Outcomes in the ACCURE Trial
United European Gastroenterology Journal · 2026
DOI: 10.1002/ueg2.70177 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Eva Visser und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Appendix, Appendectomy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds NutsOhra, Dr. Falk Pharma.
Abstract (Originalsprache)
Background
The ACCURE trial demonstrated that appendicectomy reduces relapse rates within 1 year in patients with ulcerative colitis (UC) in remission. We aimed to explore appendiceal histopathology in quiescent UC and assess its association with postoperative relapse.
Methods
Appendix specimens from Dutch participants in the ACCURE trial were reassessed by a blinded gastrointestinal pathologist using the Robarts Histopathology Index (RHI; range 0–33). Active appendiceal inflammation was defined as RHI > 3. Clinical data, preoperative endoscopic findings including peri‐appendiceal red patch (PARP), and outcomes were correlated with histopathological findings. Inter‐observer agreement between local and central scoring was assessed, along with relapse‐free survival in relation to RHI severity.
Results
Of 65 patients, 49 (75.4%) maintained remission and 16 (24.6%) relapsed within one year. Active inflammation was present in 55.4% (36/65). Inter‐observer agreement was moderate ( κ = 0.47, 95% CI 0.29–0.64, p < 0.001). Inflammation was more frequent in patients diagnosed at a younger age (median 28 vs. 34 years, p = 0.09), and greater in those with PARP (RHI 15.5 vs. 5.0, p = 0.005). Extensive epithelial neutrophil involvement (> 5% of crypts) was associated with higher relapse rates (44.4% vs. 18.0%, p = 0.05). Relapsing patients also had larger appendiceal diameters (median 9 vs. 7 mm, p = 0.03).
Conclusion
Active appendiceal inflammation is prevalent in quiescent UC and showed a trend toward association with relapse risk. Although the benefit of appendicectomy in this group cannot be confirmed on these data alone, the finding might be clinically relevant as relapse rates are significantly reduced in the appendicectomy group.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Surgery, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands.
- Department of Gastroenterology and Hepatology, Amsterdam University Medical Centres, University of Amsterdam, Amsterdam, the Netherlands.
- Institute of Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
ORCID-Profile: Eva Visser, Christianne J Buskens
Förderung
- Fonds NutsOhra
- Dr. Falk Pharma
Zitieren
APA
Visser, E., Danielsson, D., Heuthorst, L., D'Haens, G. R., Bemelman, W. A., Buskens, C. J., & Mookhoek, A. (2026). Histopathological Findings of Appendix Specimens in Quiescent Ulcerative Colitis: Correlations With Clinical Outcomes in the ACCURE Trial. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70177
Vancouver
Visser E, Danielsson D, Heuthorst L, D'Haens GR, Bemelman WA, Buskens CJ, et al. Histopathological Findings of Appendix Specimens in Quiescent Ulcerative Colitis: Correlations With Clinical Outcomes in the ACCURE Trial. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70177
BibTeX
@article{Visser2026,
author = {Visser, Eva and Danielsson, Demy and Heuthorst, Lianne and D'Haens, Geert R and Bemelman, Willem A and Buskens, Christianne J and Mookhoek, Aart},
title = {Histopathological Findings of Appendix Specimens in Quiescent Ulcerative Colitis: Correlations With Clinical Outcomes in the ACCURE Trial},
journal = {United European Gastroenterology Journal},
year = {2026},
doi = {10.1002/ueg2.70177}
}
EUVIMED